loading
Elevation Oncology Inc stock is traded at $0.385, with a volume of 403.11K. It is up +1.29% in the last 24 hours and up +21.95% over the past month. Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
See More
Previous Close:
$0.3801
Open:
$0.381
24h Volume:
403.11K
Relative Volume:
0.24
Market Cap:
$22.68M
Revenue:
-
Net Income/Loss:
$-41.95M
P/E Ratio:
-0.4639
EPS:
-0.83
Net Cash Flow:
$-38.34M
1W Performance:
+0.03%
1M Performance:
+21.95%
6M Performance:
-35.14%
1Y Performance:
-83.62%
1-Day Range:
Value
$0.38
$0.385
1-Week Range:
Value
$0.376
$0.39
52-Week Range:
Value
$0.221
$3.28

Elevation Oncology Inc Stock (ELEV) Company Profile

Name
Name
Elevation Oncology Inc
Name
Phone
(716) 371-1125
Name
Address
101 FEDERAL STREET, BOSTON
Name
Employee
34
Name
Twitter
Name
Next Earnings Date
2025-03-05
Name
Latest SEC Filings
Name
ELEV's Discussions on Twitter

Compare ELEV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ELEV
Elevation Oncology Inc
0.385 22.68M 0 -41.95M -38.34M -0.83
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.40 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
318.25 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.04 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
254.49 28.51B 3.81B -644.79M -669.77M -6.24

Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-24-25 Downgrade Stephens Overweight → Equal-Weight
Mar-21-25 Downgrade Citizens JMP Mkt Outperform → Mkt Perform
Mar-21-25 Downgrade Leerink Partners Outperform → Market Perform
Mar-21-25 Downgrade Piper Sandler Overweight → Neutral
Jan-03-25 Initiated William Blair Outperform
May-31-24 Initiated Piper Sandler Overweight
May-14-24 Initiated Stephens Overweight
Mar-01-24 Initiated JMP Securities Mkt Outperform
May-30-23 Upgrade SVB Securities Market Perform → Outperform
Dec-23-21 Initiated H.C. Wainwright Buy
View All

Elevation Oncology Inc Stock (ELEV) Latest News

pulisher
Jun 17, 2025

Analyzing Ratios: Elevation Oncology Inc (ELEV)’s Financial Story Unveiled - DWinneX

Jun 17, 2025
pulisher
Jun 16, 2025

Elevation Oncology, Inc. (NASDAQ:ELEV) Sees Large Decline in Short Interest - Defense World

Jun 16, 2025
pulisher
Jun 15, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FLS, ELEV, MTWO, CRKN on Behalf of Shareholders - GlobeNewswire Inc.

Jun 15, 2025
pulisher
Jun 14, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Jun 14, 2025
pulisher
Jun 13, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTCCRKN), Elevation Oncology, Inc. (NasdaqELEV), Sitio Royalties Corp. (NYSESTR), Vigil Neuroscience, Inc. (NasdaqV - TradingView

Jun 13, 2025
pulisher
Jun 13, 2025

Research Analysts Set Expectations for ELEV FY2025 Earnings - Defense World

Jun 13, 2025
pulisher
Jun 13, 2025

Q2 Earnings Estimate for ELEV Issued By Leerink Partnrs - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Equities Analysts Issue Forecasts for ELEV Q3 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Wedbush Forecasts Reduced Earnings for Elevation Oncology - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Elevation Oncology (NASDAQ:ELEV) Cut to “Hold” at TD Cowen - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

HC Wainwright Downgrades Elevation Oncology (NASDAQ:ELEV) to Neutral - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Elevation Oncology (NASDAQ:ELEV) Stock Rating Lowered by HC Wainwright - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Elevation Oncology (NASDAQ:ELEV) Downgraded by HC Wainwright to Neutral - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Elevation Oncology (NASDAQ:ELEV) Receives Market Perform Rating from JMP Securities - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Elevation Oncology (NASDAQ:ELEV) Lowered to Hold Rating by William Blair - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Elevation Oncology’s (ELEV) Neutral Rating Reaffirmed at HC Wainwright - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc.ELEV - Business Wire

Jun 10, 2025
pulisher
Jun 10, 2025

Elevation Oncology (ELEV) Receives Analyst Rating Update | ELEV Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

This McDonald's Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday - Benzinga

Jun 10, 2025
pulisher
Jun 10, 2025

Elevation Oncology (ELEV) Receives Downgrade from HC Wainwright & Co. | ELEV Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

TD Cowen Downgrades Elevation Oncology to Hold From Buy - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

HC Wainwright Downgrades Elevation Oncology to Neutral From Buy - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Elevation Oncology (ELEV) Downgraded by H.C. Wainwright Amid Mer - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Elevation Oncology agrees to be acquired by Concentra - The Pharma Letter

Jun 10, 2025
pulisher
Jun 10, 2025

Jane Street Group LLC Acquires 41,215 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

Millennium Management LLC Boosts Stock Holdings in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Elevation Oncology agrees to Concentra Biosciences buyout By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Elevation Oncology (ELEV) Downgraded Following Acquisition News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Elevation Oncology (ELEV) Downgraded by William Blair Following Acquisition Announcement | ELEV Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Elevation Oncology (ELEV) to be Acquired by Concentra Biosciences | ELEV Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Concentra to acquire Elevation in bid to eliminate another biotech ‘zombie’ - BioPharma Dive

Jun 09, 2025
pulisher
Jun 09, 2025

Elevation Oncology Accepts a Buyout Offer from Concentra Biosciences - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Concentra Biosciences, LLC entered into a definitive merger agreement to acquire Elevation Oncology, Inc. for $21.4 million. - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders - Business Wire

Jun 09, 2025
pulisher
Jun 09, 2025

Elevation Oncology stock soars on Concentra merger agreement By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Elevation Oncology stock soars on Concentra merger agreement - Investing.com Australia

Jun 09, 2025
pulisher
Jun 09, 2025

Concentra buys out another struggling Boston biotech - The Business Journals

Jun 09, 2025
pulisher
Jun 09, 2025

Elevation Oncology agrees to Concentra Biosciences buyout - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Elevation Oncology Says Concentra To Buy Elevation Oncology For $0.36 Per Share Plus CVR - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Elevation Oncology Merges with Concentra Biosciences - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right - PR Newswire

Jun 09, 2025
pulisher
Jun 04, 2025

Deutsche Bank AG Has $106,000 Stock Holdings in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Northern Trust Corp Purchases 59,392 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Elevation Oncology, Inc. (NASDAQ:ELEV) Receives Average Rating of “Hold” from Analysts - Defense World

Jun 02, 2025
pulisher
May 17, 2025

Elevation Oncology Reports Q1 2025 Financial Results - TipRanks

May 17, 2025
pulisher
May 16, 2025

William Blair Remains a Buy on Elevation Oncology (ELEV) - The Globe and Mail

May 16, 2025
pulisher
May 15, 2025

Elevation Oncology Explores Strategic Alternatives - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Elevation Oncology Advances Novel HER3 ADC Program While Securing Cash Runway Through 2026 - Stock Titan

May 15, 2025
pulisher
May 15, 2025

Elevation Oncology, Inc. SEC 10-Q Report - TradingView

May 15, 2025
pulisher
May 15, 2025

Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates - PR Newswire

May 15, 2025
pulisher
May 14, 2025

Allogene's Q1 Earnings In Line With Estimates, Sales Nil - Barchart.com

May 14, 2025

Elevation Oncology Inc Stock (ELEV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.73
price up icon 1.02%
$35.27
price down icon 1.78%
$21.32
price up icon 0.24%
$101.74
price down icon 2.97%
$106.14
price up icon 1.28%
biotechnology ONC
$254.49
price down icon 4.73%
Cap:     |  Volume (24h):